诺必擂停抗肿瘤作用的实验研究  

Experimental studies on antitumor effects of nobiletin in vivo and in vitro

作　　者：葛慧[1] 成美英[1] 张洪泉[1] 

机构地区：[1]扬州大学医药研究所

出　　处：《中国临床药理学与治疗学》2005年第9期988-991,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:观察诺必擂停体内外的抗肿瘤作用。方法:体内实验采用3种移植性肿瘤模型(S180、BGC823、EAC),计算各用药组抑瘤率、EAC小鼠生命延长率;体外实验采用2种肿瘤细胞株(K562、HL60),MTT法检测抑制率。结果:诺必擂停对S180、BGC823具有抑制作用,抑瘤率分别为39.11%～55.67%、36%～58%,EAC的生命延长率为15.38%～24.61%;体外,诺必擂停可抑制K562、HL60的生长,浓度在2.5～10μg·ml-1时,抑制率随浓度与时间的增加而升高。结论:诺必擂停对S180、BGC823移植性肿瘤及K562、HL60肿瘤细胞株具有明显的抑制作用,对EAC小鼠具有一定的生命延长作用。AIM： To study the anti-tumor effect of nobiletin in vivo and in vitro. METHODS： The models of Slso, BGC-823 and EAC in mice were established. Tumor growth inhibitory rates and EAC survival rate were calculated. The growth of two tumor cell lines （K562, HL-60） was observed with MTr assay in vitro. RESULTS： Nobiletin inhibited the proliferation of S180 and BGC-823 at the inhibitory rates of 39.11%-55.67% and 36%-58%, and prolong the life span of EAC mice at survival rate of 15.58%-24.61%. Nobiletin possessed inhibitory activity on the growth of K562 and HL-60 in vitro, the inhibitory rates increase in concentration and time dependent manners of in dose range of 2.5-10μg·ml^-l. CONCLUSION： Nobiletin can not only inhibit the growth of tumor cell lines, including S180, BGC-823, K562, and HL-60, but also prolong the life span of EAC mice.

关 键 词：诺必擂停 抗肿瘤 移植性肿瘤 MTT法 抑瘤率 

分 类 号：R979.1[医药卫生—药品]